SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANDRX-Reaffirm Outperform Recommendation-Gruntal Research
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PAUL ROBERT ST. ONGE who wrote (10)11/13/1996 10:10:00 PM
From: James Silverman   of 23
 
>Conservatively speaking the potential revenue totals will most likely >not reveal themselves until mid-year 97. I believe that total could >double.
Paul

Double from what level and when.
Getting a foothold internationally and building the kind of sales you are talking about is a tall order for any pharmaceutical concern. It will take years at a minimum. You also need to worry about other competitors to reach the kind of goals you are talking about. Take a look at IVX and the Verapamil once daily generic they came out with a couple of yrs back. They got a huge boost for about a yr and a half. The stock did great, then boom a second came on the mkt and sales declined and the stock never got back to former highs.

The key for ADRX and its stock over the next 3 years is when they can get Cardizem CD on the market and how long they will be the exclusive generic provider of it. Any other products you are discussing are three years away from being marketed, best case scenario. The wild card for ADRX is Procardia XL if they can file an ANDA on it the stock will jump quite a bit. Bear in mind a lot of firms have tried to create a bioequivalent of it, none have succeeded.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News